QIYU BIOTECH
Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody technology platform to build superior biopharmaceutical pipelines and explore the field of biotherapy. A big breakthrough. With the development and improvement of the company, Qiyu will have core competitiveness in more fields.
QIYU BIOTECH
Industry:
Biotechnology Health Care Medical
Founded:
2017-07-01
Address:
Shanghai, Shanghai, China
Country:
China
Total Employee:
11+
Status:
Active
Total Funding:
31.4 M USD
Similar Organizations
Cagen Bio
Cagen Bio is a vitro diagnostic reagents developer.
Dima Biotech
Dima Biotech is a cancer immunotherapy and monoclonal antibody developer.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Virogin Biotech
Virogin Biotech is an antineoplastic drug developer.
Yusu Biotech
Yusu Biotech is a hair care products developer.
Investors List
Tririver Capital
Tririver Capital investment in Series B - Qiyu Biotech
Oriza Prior
Oriza Prior investment in Series B - Qiyu Biotech
BOCOM International
BOCOM International investment in Series B - Qiyu Biotech
Shanghai Pudong Science and Technology Investment
Shanghai Pudong Science and Technology Investment investment in Series B - Qiyu Biotech
Longmen Capital
Longmen Capital investment in Series B - Qiyu Biotech
Watson Investment
Watson Investment investment in Series A - Qiyu Biotech
Jundu Investment
Jundu Investment investment in Series A - Qiyu Biotech
More informations about "Qiyu Biotech"
Qiyu Biotech 2025 Company Profile: Valuation, Funding
Qiyu Biotech General Information Description. Developer of macromolecular biopharmaceutical drug designed to treat refractory cancers and autoimmune diseases. The company's platform …See details»
Qiyu Biotech - Funding, Financials, Valuation & Investors
Qiyu Biotech is an innovative macromolecular drug developer. New. Resources. Advanced Search. Start Free Trial ... Experience the new Crunchbase, powered by AI . Experience the …See details»
About QY - QY BIOTECH
Shenzhen Qiyu Biotechnology Co., Ltd. Shenzhen Qiyu Biotechnology Co., Ltd. was established in 2021 by a group of scientists who are committed to developing innovative products for the …See details»
Qiyu Biotech of Shanghai Completes A Funding Round …
Aug 14, 2019 Qiyu Biotechnology, a Shanghai startup located in Zhangjiang Hi-Tech Park, completed a Series A round that raised “tens of millions of RMB” …See details»
Qiyu Biotech - Headquarter Location, Corporate Office Address …
Qiyu Biotech is Biotechnology in China that focus on developer business. They cover business area such as developer, macromolecular biopharmaceutical drug, refractory cancer, …See details»
Qiyu Bio Lands Tens of Millions of Yuan in Series A Financing
Qiyu Biotechnology（Qiyu Bio） has announced the completion of tens of millions yuan in series A financing, jointly invested by Jundu Investment and Wosheng Capital. This round of …See details»
Shenzhen Qiyu Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Explore Shenzhen Qiyu Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 2 literature.See details»
Qiyu Biotechnology (Shanghai) Co., Ltd., a research and …
Recently, Qiyu Biotechnology (Shanghai) Co., Ltd. received tens of millions of yuan of pre-B round investment from New Henglida Capital and other related institutions. Founded in July …See details»
Beijing Qiyu Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Explore Beijing Qiyu Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, . ... Explore the financial positions of over 360K organizations with Synapse. login. or. …See details»
Guangzhou Qiyu Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Last update 19 Sep 2024. Guangzhou Qiyu Biotechnology Co., Ltd. Private Company |See details»
Qiyu Biotech - Crunchbase
Qiyu Biotech is an innovative macromolecular drug developer. Experience the new Crunchbase, powered by AISee details»
Tri River Capital - teaserclub.com
Qi Xiangdong, founder of Qiyu Bio, said: “Innovation is the starting and future of Qiyu Bio, and it is the core driving force of enterprise development. Qiyu Bio will use the first-class antibody …See details»
CN114605522 - Drug Targets, Indications, Patents - Synapse
CN114605522, Initially developed by Shenzhen Qiyu Biotechnology Co., Ltd., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active ...See details»
Qiyu Biotechnology Co., Ltd. announced that it has received CNY …
Dec 22, 2021 Qiyu Biotechnology (Shanghai) Co., Ltd. announced that it has received nearly CNY 200 million in a round of funding led by BOCOM International Holdings Company Limited …See details»
Qiyu Biotech of Shanghai Completes A Funding Round for Novel …
Aug 14, 2019 Qiyu Biotechnology, a Shanghai startup located in Zhangjiang Hi-Tech Park, completed a Series A round that raised "tens of millions of RMB" from Jundu Investment and …See details»
Chongqing Qiyu Biotechnology Co., Ltd.: Drug pipelines, Patents ...
Jul 15, 2023 Explore Chongqing Qiyu Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
Partnerships with Indigenous Peoples for an ethical bioeconomy
6 days ago The World Health Organization (WHO) reports that approximately 40% of the commercial drugs today derive from plants and Traditional Medicine 3.As biotechnology …See details»
Skin Care Products | Cosmetics | Disinfection - Guangzhou Qiyu ...
At Guangzhou Qiyu Biotechnology Co., Ltd., we offer a diverse and carefully curated selection of products designed to enrich your daily health and beauty routine. Guangzhou Qiyu …See details»
Series B - Qiyu Biotech - 2021-12-23 - Crunchbase
Organization Name . Qiyu Biotech . Announced Date Dec 23, 2021; Funding Type ...See details»
Hengrui Medicine's Apatinib and Qiyu Bio-Q-1802 announced a …
The product "Q-1802" is an innovative drug for the treatment of tumors developed by Qiyu Biotech. It is a double antibody that simultaneously targets Claudin 18.2 and PD-L1. Due o its …See details»